Sugi Predict

Sugi Predict / Compounds / SCHEMBL893905

SCHEMBL893905

SCHEMBL893905

O=C(O)c1ccc(NS(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.73
▸ CA9 Q16790 3/20 0.73
▸ CA1 P00915 2/20 0.73
▸ CA2 P00918 2/20 0.73
▸ KMT2A Q03164 8/20 0.69
▸ MEN1 O00255 7/20 0.69
▸ ALDH1A1 P00352 1/20 0.69
▸ PKM P14618 1/20 0.69
▸ KEAP1 Q14145 2/20 0.68
▸ IL1RN P18510 1/20 0.68
▸ ERAP1 Q9NZ08 1/20 0.68
▸ MAPT P10636 2/20 0.66
▸ POLB P06746 1/20 0.66
▸ GAA P10253 1/20 0.62
▸ ITGA1 P56199 1/20 0.62
▸ GFER P55789 1/20 0.61
▸ HDAC3 O15379 1/20 0.61
▸ HDAC4 P56524 1/20 0.61
▸ HDAC1 Q13547 1/20 0.61
▸ HDAC7 Q8WUI4 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3715141 0.93 CA12 (0.75) CA12CA9CA1CA2KMT2A
SCHEMBL3563796 0.91 HDAC1 (0.66) CA12CA9CA1CA2KMT2A
SCHEMBL5048564 0.90 UQCRB (0.71) CA12CA9CA1CA2KMT2A
SCHEMBL3563809 0.87 MEN1 (0.62) CA12CA9CA1CA2KMT2A
SCHEMBL28614182 0.87 KMT2A (0.61) CA12CA9CA1CA2KMT2A
SCHEMBL810795 0.86 KMT2A (0.91) CA12CA9CA1CA2KMT2A
SCHEMBL7932062 0.86 CA12 (0.73) CA12CA9CA1CA2KMT2A
SCHEMBL3081178 0.86 MEN1 (0.65) CA12CA9CA1CA2KMT2A
SCHEMBL2201204 0.86 CA12 (0.87) CA12CA9KMT2AMEN1ALDH1A1
SCHEMBL95742 0.84 CA12 (0.71) CA12CA9CA1CA2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11793806-B2 Pyruvate kinase activators for use in therapy AGIOS PHARMACEUTICALS, INC. (US) 2023-10-24 — — US disclosed
US-11793806-B2 Pyruvate kinase activators for use in therapy AGIOS PHARMACEUTICALS, INC. (US) 2023-10-24 — — US disclosed
US-RE49582-E1 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2023-07-18 — — US disclosed
US-RE49582-E1 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2023-07-18 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20210220351-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY AGIOS PHARMACEUTICALS, INC. 2021-07-22 — — US disclosed
US-10988448-B2 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC. (US) 2021-04-27 — — US disclosed
US-20200289502-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY AGIOS PHARMACEUTICALS, INC. 2020-09-17 — — US disclosed
US-10632114-B2 Pyruvate kinase activators for use in therapy AGIOS PHARMACEUTICALS, INC. (US) 2020-04-28 — — US disclosed
US-5709861-A PEPTIDES WITH ANTIGENS AND PROCESS FOR MIXING EMISPHERE TECHNOLOGIES, INC. (US) 1998-01-20 — — US disclosed
EP-0812212-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS Emisphere Technologies, Inc. (US) 1997-12-17 — — EP disclosed
EP-0784469-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS Emisphere Technologies, Inc. (US) 1997-07-23 — — EP disclosed
EP-0696208-A4 ORAL DRUG DELIVERY COMPOSITIONS AND METHODS EMISPHERE TECH INC (US) 1997-01-29 — — EP disclosed
WO-1996021464-A9 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS — 1996-11-14 — — WO disclosed
WO-1996021464-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECHNOLOGIES, INC. (US) 1996-07-18 — — WO disclosed
WO-1996012474-A1 COMPOSITIONS FOR THE DELIVERY OF ANTIGENS EMISPHERE TECHNOLOGIES, INC. (US) 1996-05-02 — — WO disclosed
EP-0696208-A1 ORAL DRUG DELIVERY COMPOSITIONS AND METHODS Emisphere Technologies, Inc. (US) 1996-02-14 — — EP disclosed
WO-1994023767-A1 ORAL DRUG DELIVERY COMPOSITIONS AND METHODS EMISPHERE TECHNOLOGIES, INC. (US) 1994-10-27 — — WO disclosed
EP-0159291-A1 Ink composition for the ink-jet printing process CIBA-GEIGY AG (CH) 1985-10-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11793806-B2 Pyruvate kinase activators for use in therapy PCK1, PDK3, PDK2 CA12 3371/4885CA9 2612/4885CA1 3928/4885
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 CA12 1212/4885CA9 1741/4885CA1 1353/4885
US-20210220351-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY PCK1, PDK3, PDK2 CA12 3371/4885CA9 2612/4885CA1 3928/4885
US-10988448-B2 Therapeutic compounds and compositions PDK1, PDK2, PDK3 CA12 2465/4885CA9 1720/4885CA1 3941/4885
US-20200289502-A1 PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY PCK1, PDK3, PDK2 CA12 3371/4885CA9 2612/4885CA1 3928/4885
US-10632114-B2 Pyruvate kinase activators for use in therapy PCK1, PDK3, PDK2 CA12 3371/4885CA9 2612/4885CA1 3928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.